2021
DOI: 10.1111/sji.13031
|View full text |Cite
|
Sign up to set email alerts
|

Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab

Abstract: Severe eosinophilic asthma (SEA) has been associated with T‐helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for severe cases. Mepolizumab, an IL‐5 antagonist, is indicated for the treatment of severe asthma. Regulatory T cells (Tregs) suppress inflammation by secreting cytokines that inhibit Th2 cell proliferation. We investigated peripheral Treg, CD4, CD8, CD19 and NK cell percentages and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 38 publications
0
9
1
Order By: Relevance
“…15,16 Our data also support observations by recent smaller studies focused on the clinical outcomes and underlying immunological changes following anti-IL5 or anti-IL5Rα therapy. 7,[25][26][27][28] However, our findings stand in contrast to the indirect comparison performed by Busse et al, who had seen an advantage for mepolizumab in terms of asthma control and reduction of exacerbations. 17 It is important to note, however, that Bourdin et al, Cabon et al, and Busse et al re-analyzed existing phase-3 drug trial data by using the respective control groups as references to perform an indirect comparison between treatment groups.…”
Section: Discussioncontrasting
confidence: 99%
“…15,16 Our data also support observations by recent smaller studies focused on the clinical outcomes and underlying immunological changes following anti-IL5 or anti-IL5Rα therapy. 7,[25][26][27][28] However, our findings stand in contrast to the indirect comparison performed by Busse et al, who had seen an advantage for mepolizumab in terms of asthma control and reduction of exacerbations. 17 It is important to note, however, that Bourdin et al, Cabon et al, and Busse et al re-analyzed existing phase-3 drug trial data by using the respective control groups as references to perform an indirect comparison between treatment groups.…”
Section: Discussioncontrasting
confidence: 99%
“…The phenotypes of T reg and B reg cells through flow cytometric analysis were performed as previously reported [ 29 , 30 , 31 ]. The panel of monoclonal antibodies, including T regs (human regulatory T cell cocktail; BD Biosciences), fluorescein isothiocyanate anti‐human CD4 (clone SK3), phycoerythrin‐cyanin 7 (PE‐Cy7) anti‐human CD25 (clone 2A3) and Alexa Fluor ® 647 anti‐human CD127 (clone HIL‐7R‐M21), were used.…”
Section: Methodsmentioning
confidence: 99%
“…The following lung function parameters were recorded according to ATS/ERS standards using a Jaeger body plethysmograph with corrections for temperature and barometric pressure: forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/ activity mediated by IL-10, IL-35 and TGF-beta release, inducing activation of Tregs [12][13][14][15]. Types of human Breg cells have different surface markers characterising different subsets, such as CD27 + CD24 hi cells, CD24 hi CD38 hi immature/transitional B cells and CD5 + CD1d hi [16].…”
Section: Lung Function Testsmentioning
confidence: 99%